Monoclonal antibodies in severe asthma: outcomes from real-world data
In routine clinical practice, benralizumab, mepolizumab, omalizumab, and reslizumab were associated with improvements in asthma control, lung function, and reduction in exacerbations over 12 months. Benralizumab and reslizumab were associated with the greatest reductions in eosinophil counts. Our findings suggest comparable effectiveness across biologics. High adherence and treatment persistence support their feasibility in real-world settings. These results underscore the relevance of phenotype-driven therapy selection and highlight the need for long-term monitoring to optimize outcomes in severe asthma management.
Authors
- F Garcia-Moreno
- Elena Lobato‐Matilla
- Ana Herranz (ORCID: https://orcid.org/0000-0003-1010-4295)
- Esther Chamorro-de-Vega (ORCID: https://orcid.org/0000-0002-2654-7165)
- Rosa Romero‐Jiménez (ORCID: https://orcid.org/0000-0002-6348-4001)
- Vicente Escudero‐Vilaplana (ORCID: https://orcid.org/0000-0003-4417-8321)
- Álvaro Narrillos-Moraza (ORCID: https://orcid.org/0000-0002-6366-5339)
- María Sanjurjo‐Sáez (ORCID: https://orcid.org/0000-0002-8523-3721)
- Paula Ruiz-Briones (ORCID: https://orcid.org/0000-0003-4285-148X)
- Silvia del-Barrio-Buesa
- María Martín-Bartolomé
- Julia García-de-Pedro
- Francisco Javier de-Castro-Martínez
- María Esther Durán-García
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital General Universitario Gregorio Marañón (ES)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-08-11
- DOI
- https://doi.org/10.3389/fmed.2025.1635688
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00